Strides Pharma Science has released its unaudited consolidated financial results for the quarter and nine months ended December 31, 2025. The company reported a total income of ₹13,015.08 million for the quarter. The results reflect the ongoing financial performance of the company’s operations across both continuing and discontinued business segments. Discontinued operations contributed significantly to overall earnings due to a one-time gain. The board approved these results on January 30, 2026.
Financial Performance Overview
Strides Pharma Science announced its unaudited consolidated financial results for the third quarter of fiscal year 2026, ending December 31, 2025. Total income for the quarter reached ₹13,015.08 million, compared to ₹12,479.71 million in the preceding quarter.
Key Financial Metrics
Significant financial details from the report include:
- Total Expenses: The company’s total expenses amounted to ₹10,527.03 million.
- Profit Before Tax: The profit before tax from continuing operations was reported at ₹2,454.75 million.
- Net Profit: The net profit after tax from continuing operations stood at ₹2,081.22 million.
Segment Performance
A significant portion of the company’s profit is attributable to discontinued operations, primarily due to gains on disposal of assets. Discontinued operations contributed ₹31,881.07 million to the overall profit during this period.
Additional Highlights
- Total Comprehensive Income: The total comprehensive income for the period was reported at ₹2,180.02 million.
- Earnings Per Share (EPS): The basic and diluted EPS from continuing operations were ₹21.93 and ₹21.92 respectively. The overall Basic and diluted EPS stood at ₹381.81 and ₹381.77 due to income from discontinued operations.
Change in Auditors
The financial statements were reviewed by BSR & Co. LLP, Chartered Accountants. These results, reviewed by the Audit Committee, were approved by the Board of Directors on January 30, 2026.
Source: BSE
